NRBO News and Press, NeuroBo Pharmaceuticals Inc. From 11/13/23

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...

NeuroBo Pharmaceuticals Inc. (NRBO) is expected to report for Q3 2023

NeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D. PR Newswire BOSTON , Nov. 6, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform ...

2023-10-20 15:00:13 ET More on the markets S&P 500 Will Likely Underperform And 5% Money Markets Are NOT The Answer Equities Climbing A Wall Of Worry (Technical Analysis) SPY: Short-Term Bounce Testing The Downtrends (Technical Analysis) Here is why you s...

NeuroBo to Present at the H.C. Wainwright 7th Annual NASH Investor Conference PR Newswire BOSTON , Oct. 17, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases,...

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH PR Newswire Two-Part Design Provides Optionality for Interim Analysis in First Half of 2024 Full Data Readout Expected in the Second Half of 2024 ...

2023-08-14 08:12:27 ET NeuroBo Pharmaceuticals ( NASDAQ: NRBO ) has announced the appointment of current Board member, Hyung Heon Kim, as the Co.'s CEO and President, effective immediately.. Mr. Kim succeeds Joseph Hooker, who served as interim CEO and President since...

2023-08-10 11:50:21 ET NeuroBo Pharmaceuticals press release ( NASDAQ: NRBO ): Q2 GAAP EPS of -$0.02. Cash and Cash Equivalents were $28.7 million as of June 30, 2023, compared with $33.4 million as of December 31, 2022. The company expects its cash position will be adequa...

NeuroBo Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Dosing of First Patient in Phase 2a Clinical Trial of DA-1241 Expected September 2023 Cash and Cash Equivalents of $28.7 Million , Expected to Fund t...

NeuroBo Pharmaceuticals Receives First Site IRB Approval for its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH PR Newswire BOSTON , Aug. 3, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnolog...